Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-06-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neuroblastic tumors are childhood neoplasms that possess amino acid decarboxylase (AADC) activity and Meta-iodobenzylguanidine(MIBG), they can theoretically be imaged by (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) and (123)I-Meta-iodobenzylguanidine((123)I-MIBG) PET, they are new and specific diagnostic and follow-up tools for neuroendocrine tumors. In this study, we explored the accuracy and clinical role of (18)F-FDOPA and (123)I-MIBG PET in neuroblastic tumors.

METHODS:

Patients with tissue-proven neuroblastic tumors receiving (18)F-FDOPA PET or (123)I-MIBG at initial diagnosis or during follow-ups were enrolled. The sensitivity and specificity of (18)F-FDOPA or (123)I-MIBG PET were compared to each other and compared to(18)F-FDG PET, using tumor histology as the standard.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients

NCT00304694

Nasopharyngeal Cancer

UNKNOWN

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

NCT03541720

Neuroblastoma Pheochromocytoma

ACTIVE_NOT_RECRUITING EARLY_PHASE1

18F-mFBG PET Imaging in the Evaluation of Neuroblastoma

NCT06852807

Neuroblastoma

RECRUITING

Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

NCT02539433

Neuroendocrine Tumors

COMPLETED NA

Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions: Comparison With MIBI Scan.

NCT03555487

Parathyroid Diseases

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuroblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) Diagnosed by clinical criteria(one of below)

1. Proved as Neuroblastoma by a pathological section
2. Bone meta with 24 hrs urine VMA(Vanillylmandelic acid )or HVA (Homovanillic acid) elevated
3. CT or MRI found tumor around adrenal gland or Neuroblastic tumor
* (2) Age between 0-30 years old，Body weight over 2.5kg
* (3) Signed Inform Consent Form

Exclusion Criteria

* (1)AST and ALT \> 200U/L、Cre \> 2.5mg/dl
* (2)Allerg to 18F-dopa、123I-MIBG
* (3)Subject not fit this study(assessed by PI)
* (4)No more need to arrenge PET because disease progress, assessed by VS

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No